Janssen Neuroscientist Appointed To Scientific Advisory Board Of Global Dementia Discovery Fund

Johnson & Johnson announced that Husseini K. Manji, MD, FRCPC, Global Therapeutic Head for Neuroscience at Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has been appointed to the Scientific Advisory Board of the newly launched, U.K. Government-led global Dementia Discovery Fund (DDF). Johnson & Johnson has invested $10 million in the DDF, which was created to deliver new treatment approaches for dementia by 2025. The DDF, led by the UK Government Department of Health, will work with universities, academic institutions, and the biotechnology and pharmaceutical industry internationally to identify novel dementia and Alzheimer's . . .